174 Peri-Procedural Warfarin Bridging Evaluation for Patients with Atrial Fibrillation Enrolled in an Anticoagulation Management Service
Introduction: The 2023 AHA/ACC/HRS guideline recommends against peri-procedural bridging of warfarin in patients with atrial fibrillation (AF) based on CHA2DS2-VASc scores alone without prior thromboembolic (TE) events or additional risk factors. At our institution, the decision to bridge in patients with AF with moderate-to-high TE risk is driven by clinical judgment and patient-specific factors such as history of mechanical heart valve, lupus anticoagulant, or recurrent thromboembolism. Objective: To evaluate our current institutional peri-procedural practices and its impact on TE and bleeding events.
Authors
- Renée Chow (ORCID: https://orcid.org/0000-0002-1324-5969)
- Katelyn W. Sylvester (ORCID: https://orcid.org/0000-0001-9208-2354)
- Hassan Sinan (ORCID: https://orcid.org/0009-0000-4402-3499)
- Jean M. Connors (ORCID: https://orcid.org/0000-0001-6445-582X)
- Eunjoo Kang (ORCID: https://orcid.org/0009-0009-0759-5784)
- Mengyan Li (ORCID: https://orcid.org/0000-0002-8580-5283)
Institutions
- Brigham and Women's Hospital (US)
Publication Details
- Journal
- Research and Practice in Thrombosis and Haemostasis
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1016/j.rpth.2025.102796
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00